Joseph Najbauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joseph Najbauer has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Jan Barciszewski
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Z. Noskowskiego 12/14, 61-704 Poznan, Poland
1 shared publication Nikola Kraljik
Institute of Public Health for the Osijek-Baranja County
1 shared publication- Patrick M. Perrigue
Institute of Bioorganic Chemistry of the Polish Academy of Sciences, Zygmunta Noskowskiego 12/14, 61-704 Poznań, Poland
1 shared publication Péter Németh
University of Pécs Medical School
1 shared publication
Latest Publications
- 1 April 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1865 (2) , 237-244
Histone demethylase JMJD3 at the intersection of cellular senescence and cancer
- 1 April 2016
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1865 (2) , 237-244
Histone demethylase JMJD3 at the intersection of cellular senescence and cancer
- 29 August 2014
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 20 (4) , 789-797
Glioma Stem Cells: Markers, Hallmarks and Therapeutic Targeting by Metformin
Malignant gliomas are among the deadliest primary brain tumors. Despite multimodal therapy and advances in chemotherapy, imaging, surgical and radiation techniques, these tumors remain virtually incurable. Glioma stem cells may be responsible for resistance to traditional therapies and tumor recurrence. Therefore, elimination of glioma stem cells may be crucial for achieving therapeutic efficacy. Metformin, a small molecule drug widely used in the therapy of type 2 diabetes, has shown significant anti-tumor effects in patients with breast cancer and prostate cancer. Recent preclinical data suggest that metformin also has therapeutic effects against glioma. Here we review the markers and hallmarks of glioma stem cells, and the molecular mechanisms involved in therapeutic targeting of glioma stem cells by metformin.
- 29 August 2014
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 20 (4) , 789-797
Glioma Stem Cells: Markers, Hallmarks and Therapeutic Targeting by Metformin
Malignant gliomas are among the deadliest primary brain tumors. Despite multimodal therapy and advances in chemotherapy, imaging, surgical and radiation techniques, these tumors remain virtually incurable. Glioma stem cells may be responsible for resistance to traditional therapies and tumor recurrence. Therefore, elimination of glioma stem cells may be crucial for achieving therapeutic efficacy. Metformin, a small molecule drug widely used in the therapy of type 2 diabetes, has shown significant anti-tumor effects in patients with breast cancer and prostate cancer. Recent preclinical data suggest that metformin also has therapeutic effects against glioma. Here we review the markers and hallmarks of glioma stem cells, and the molecular mechanisms involved in therapeutic targeting of glioma stem cells by metformin.